{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T23:30:42Z","timestamp":1648769442628},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,7,31]],"date-time":"2017-07-31T00:00:00Z","timestamp":1501459200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s12471-017-1023-y","type":"journal-article","created":{"date-parts":[[2017,7,31]],"date-time":"2017-07-31T11:31:13Z","timestamp":1501500673000},"page":"655-663","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention or after acute coronary syndrome"],"prefix":"10.1007","volume":"25","author":[{"given":"J. M.","family":"ten Berg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Zwart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. W. J.","family":"van \u2019t Hof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Liem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Waltenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. J.","family":"de Winter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. W.","family":"Jukema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,31]]},"reference":[{"key":"1023_CR1","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"S Windecker","year":"2014","unstructured":"Windecker S, Kolh P, Alfonso F, et al. 2014 ESC\/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart\u00a0J. 2014;35:2541\u2013619.","journal-title":"Eur Heart J"},{"key":"1023_CR2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1161\/CIR.0000000000000404","volume":"134","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA, et al. 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines: an update of the 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention, 2011 ACCF\/AHA guideline for coronary artery bypass graft surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stableiIschemic heart disease, 2013 ACCF\/AHA guideline for the management of ST-Elevation myocardial infarction, 2014 AHA\/ACC guideline for the management of patients with Non-ST-Elevation acute coronary syndromes, and 2014 ACC\/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134:123.","journal-title":"Circulation"},{"key":"1023_CR3","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jacc.2016.03.512","volume":"68","author":"JA Bittl","year":"2016","unstructured":"Bittl JA, Baber U, Bradley SM, Wijeysundera DN. Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC\/AHA guideline focused update on duration of dual Antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. J\u00a0Am Coll Cardiol. 2016;68:1116\u201339.","journal-title":"J Am Coll Cardiol"},{"key":"1023_CR4","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2008.12.055","volume":"53","author":"JW Werkum van","year":"2009","unstructured":"van Werkum JW, Heestermans AA, Zomer AC, et\u00a0al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J\u00a0Am Coll Cardiol. 2009;53:1399\u2013409.","journal-title":"J Am Coll Cardiol"},{"key":"1023_CR5","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1001\/jama.293.17.2126","volume":"293","author":"I Iakovou","year":"2005","unstructured":"Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126\u201330.","journal-title":"JAMA"},{"key":"1023_CR6","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1161\/CIRCULATIONAHA.106.618066","volume":"113","author":"JA Spertus","year":"2006","unstructured":"Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006;113:2803\u20139.","journal-title":"Circulation"},{"key":"1023_CR7","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1093\/eurheartj\/ehp275","volume":"30","author":"S Schulz","year":"2009","unstructured":"Schulz S, Schuster T, Mehilli J, et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a\u00a04-year period. Eur Heart\u00a0J. 2009;30:2714\u201321.","journal-title":"Eur Heart J"},{"key":"1023_CR8","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","volume":"373","author":"P Urban","year":"2015","unstructured":"Urban P, Meredith IT, Abizaid A, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N\u00a0Engl J Med. 2015;373:2038\u201347.","journal-title":"N Engl J Med"},{"key":"1023_CR9","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jacc.2014.11.053","volume":"65","author":"M Valgimigli","year":"2015","unstructured":"Valgimigli M, Patialiakas A, Thury A, et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J\u00a0Am Coll Cardiol. 2015;65:805\u201315.","journal-title":"J Am Coll Cardiol"},{"key":"1023_CR10","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","volume":"64","author":"A Colombo","year":"2014","unstructured":"Colombo A, Chieffo A, Frasheri A, et al. Second-generation drug-eluting stent implantation followed by 6\u2011 versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J\u00a0Am Coll Cardiol. 2014;64:2086\u201397.","journal-title":"J Am Coll Cardiol"},{"key":"1023_CR11","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","volume":"125","author":"HC Gwon","year":"2012","unstructured":"Gwon HC, Hahn JY, Park KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012;125:505\u201313.","journal-title":"Circulation"},{"key":"1023_CR12","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","volume":"60","author":"BK Kim","year":"2012","unstructured":"Kim BK, Hong MK, Shin DH, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3\u2011month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J\u00a0Am Coll Cardiol. 2012;60:1340\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"1023_CR13","first-page":"2510","volume":"310","author":"F Feres","year":"2013","unstructured":"Feres F, Costa RA, Abizaid A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013;310:2510\u201322.","journal-title":"JAMA"},{"key":"1023_CR14","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","volume":"36","author":"S Schulz-Schupke","year":"2015","unstructured":"Schulz-Schupke S, Byrne RA, Ten Berg JM, et al. ISAR-SAFE: a\u00a0randomized, double-blind, placebo-controlled trial of 6 vs. 12\u00a0months of clopidogrel therapy after drug-eluting stenting. Eur Heart\u00a0J. 2015;36:1252\u201363.","journal-title":"Eur Heart J"},{"key":"1023_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw627","author":"T Palmerini","year":"2017","unstructured":"Palmerini T, Della Riva D, Benedetto U, et al. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11\u2009473 patients. Eur Heart\u00a0J. 2017; doi:\n                        10.1093\/eurheartj\/ehw627\n                        \n                    .","journal-title":"Eur Heart J"},{"key":"1023_CR16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ahj.2016.04.016","volume":"178","author":"C Camaro","year":"2016","unstructured":"Camaro C, Damen SAJ, Brouwer MA, et al. Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial. Am Heart\u00a0J. 2016;178:37\u201344.","journal-title":"Am Heart J"},{"key":"1023_CR17","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","volume":"125","author":"M Valgimigli","year":"2012","unstructured":"Valgimigli M, Campo G, Monti M, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a\u00a0randomized multicenter trial. Circulation. 2012;125:2015\u201326.","journal-title":"Circulation"},{"key":"1023_CR18","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(14)60612-7","volume":"384","author":"JP Collet","year":"2014","unstructured":"Collet JP, Silvain J, Barthelemy O, et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a\u00a0randomised trial. Lancet. 2014;384:1577\u201385.","journal-title":"Lancet"},{"key":"1023_CR19","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/S0140-6736(15)60263-X","volume":"385","author":"T Palmerini","year":"2015","unstructured":"Palmerini T, Benedetto U, Bacchi-Reggiani L, et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a\u00a0pairwise and Bayesian network meta-analysis of randomised trials. Lancet. 2015;385:2371\u201382.","journal-title":"Lancet"},{"key":"1023_CR20","doi-asserted-by":"crossref","first-page":"h1618","DOI":"10.1136\/bmj.h1618","volume":"350","author":"EP Navarese","year":"2015","unstructured":"Navarese EP, Andreotti F, Schulze V, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ. 2015;350:h1618.","journal-title":"BMJ"},{"key":"1023_CR21","doi-asserted-by":"crossref","first-page":"118","DOI":"10.7326\/M15-0083","volume":"163","author":"FA Spencer","year":"2015","unstructured":"Spencer FA, Prasad M, Vandvik PO, et al. Longer- versus shorter-duration dual-antiplatelet therapy after drug-eluting stent placement: a systematic review and meta-analysis. Ann Intern Med. 2015;163:118\u201326.","journal-title":"Ann Intern Med"},{"key":"1023_CR22","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.jacc.2017.02.029","volume":"69","author":"T Palmerini","year":"2017","unstructured":"Palmerini T, Bacchi Reggiani L, Della Riva D, et al. Bleeding-related deaths in relation to the duration of dual-antiplatelet therapy after coronary stenting. J\u00a0Am Coll Cardiol. 2017;69:2011\u201322.","journal-title":"J Am Coll Cardiol"},{"key":"1023_CR23","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0140-6736(14)62052-3","volume":"385","author":"S Elmariah","year":"2015","unstructured":"Elmariah S, Mauri L, Doros G, et al. Extended duration dual antiplatelet therapy and mortality: a\u00a0systematic review and meta-analysis. Lancet. 2015;385:792\u20138.","journal-title":"Lancet"},{"key":"1023_CR24","first-page":"390","volume":"37","author":"JA Udell","year":"2016","unstructured":"Udell JA, Bonaca MP, Collet J, et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a\u00a0collaborative meta-analysis of randomized trials. Eur Heart\u00a0J. 2016;37:390\u20139.","journal-title":"Eur Heart J"},{"key":"1023_CR25","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","volume":"371","author":"L Mauri","year":"2014","unstructured":"Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30\u00a0months of dual antiplatelet therapy after drug-eluting stents. N\u00a0Engl J Med. 2014;371:2155\u201366.","journal-title":"N Engl J Med"},{"key":"1023_CR26","first-page":"378","volume":"37","author":"L Mauri","year":"2016","unstructured":"Mauri L, Elmariah S, Yeh RW, et\u00a0al. Causes of late mortality with dual antiplatelet therapy after coronary stents. Eur Heart\u00a0J. 2016;37:378\u201385.","journal-title":"Eur Heart J"},{"key":"1023_CR27","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","volume":"372","author":"MP Bonaca","year":"2015","unstructured":"Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N\u00a0Engl J Med. 2015;372:1791\u2013800.","journal-title":"N Engl J Med"},{"key":"1023_CR28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/eurheartj\/ehv712","volume":"37","author":"T Palmerini","year":"2016","unstructured":"Palmerini T, Stone GW. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: conceptual evolution based on emerging evidence. Eur Heart\u00a0J. 2016;37:353\u201364.","journal-title":"Eur Heart J"},{"key":"1023_CR29","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jacc.2015.06.1323","volume":"66","author":"P G\u00e9n\u00e9reux","year":"2015","unstructured":"G\u00e9n\u00e9reux P, Giustino G, Witzenbichler B, et al. Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention. J\u00a0Am Coll Cardiol. 2015;66:1036\u201345.","journal-title":"J Am Coll Cardiol"},{"key":"1023_CR30","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.jcin.2016.04.037","volume":"9","author":"SJ Brener","year":"2016","unstructured":"Brener SJ, Kirtane AJ, Stuckey TD, et al. The impact of timing of ischemic and hemorrhagic events on mortality after percutaneous coronary intervention: the ADAPT-DES study. JACC Cardiovasc Interv. 2016;9:1450\u20137.","journal-title":"JACC Cardiovasc Interv"},{"key":"1023_CR31","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"M Roffi","year":"2016","unstructured":"Roffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart\u00a0J. 2016;37:267\u2013315.","journal-title":"Eur Heart J"},{"key":"1023_CR32","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","volume":"315","author":"RW Yeh","year":"2016","unstructured":"Yeh RW, Secemsky EA, Kereiakes DJ, et\u00a0al. Development and validation of a\u00a0prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315:1735\u201349.","journal-title":"JAMA"},{"issue":"6","key":"1023_CR33","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrcardio.2015.32","volume":"12","author":"DS Ong","year":"2015","unstructured":"Ong DS, Jang IK. Causes, assessment, and treatment of stent thrombosis \u2013 intravascular imaging insights. Nat Rev Cardiol. 2015;12(6):325\u201336.","journal-title":"Nat Rev Cardiol"},{"key":"1023_CR34","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jama.284.7.835","volume":"284","author":"EM Antman","year":"2000","unstructured":"Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina\/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284:835\u201342.","journal-title":"JAMA"},{"key":"1023_CR35","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.291.22.2727","volume":"291","author":"KA Eagle","year":"2004","unstructured":"Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6\u2011month postdischarge death in an international registry. JAMA. 2004;291:2727\u201333.","journal-title":"JAMA"},{"key":"1023_CR36","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1\u2011year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093\u2013100.","journal-title":"Chest"},{"key":"1023_CR37","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1161\/CIRCULATIONAHA.108.828541","volume":"119","author":"S Subherwal","year":"2009","unstructured":"Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the\u00a0CRUSADE\u00a0(Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC\/AHA Guidelines)\u00a0bleeding\u00a0score. Circulation. 2009;119:1873\u201382.","journal-title":"Circulation"},{"key":"1023_CR38","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, et\u00a0al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart\u00a0J. 2016;37:2893\u2013962.","journal-title":"Eur Heart J"},{"key":"1023_CR39","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/S0195-668X(03)00485-8","volume":"24","author":"M Moscucci","year":"2003","unstructured":"Moscucci M, Fox KAA, Cannon CP, et\u00a0al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart\u00a0J. 2003;24:1815\u201323.","journal-title":"Eur Heart J"},{"key":"1023_CR40","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/eurheartj\/ehv103","volume":"36","author":"RK Binder","year":"2015","unstructured":"Binder RK, L\u00fcscher TF. Duration of dual antiplatelet therapy after coronary artery stenting: where is the sweet spot between ischaemia and bleeding? Eur Heart\u00a0J. 2015;36:1207\u201311.","journal-title":"Eur Heart J"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12471-017-1023-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-017-1023-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-017-1023-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T14:55:43Z","timestamp":1510930543000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12471-017-1023-y"}},"subtitle":["Practical lessons from a\u00a0review"],"short-title":[],"issued":{"date-parts":[[2017,7,31]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1023"],"URL":"https:\/\/doi.org\/10.1007\/s12471-017-1023-y","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,31]]}}}